Source: Annual Congress 2003 - Issues surrounding drug delivery
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. A. G. Demoncheaux, J. W. Fenner, B. Brook, R. Hose, D. Bee, K. McCormack, T. W. Higenbottam (Sheffield, Loughborough, United Kingdom). Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease. Eur Respir J 2003; 22: Suppl. 45, 2994

Member's Comments

No comment yet.

Related content which might interest you: Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma? Source: Eur Respir J, 58 (3) 2100304; 10.1183/13993003.00304-2021 Year: 2021 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Hepatotoxic reactions in rats after administration of component schemes of reserve Anti-TB drugs with different safety profile Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling Source: Annual Congress 2009 - New bronchodilators Year: 2009 Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004 Validation of FEV1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Effect of long-term imatinib treatment in a severe preclinical PAH rat model: An insight into pulmonary perfusion using a novel casting method Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012